<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00646789</url>
  </required_header>
  <id_info>
    <org_study_id>0633-019</org_study_id>
    <secondary_id>MK0633-019</secondary_id>
    <secondary_id>2008_514</secondary_id>
    <nct_id>NCT00646789</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability and Plasma Concentration Profiles of MK0633 in Asthmatic Children Aged 12 to Less Than 16 Years (0633-019)</brief_title>
  <official_title>A Multicenter, Open-Label, Single Dose Study to Evaluate the Safety, Tolerability and Plasma Concentration Profiles of MK0633 in Asthmatic Children Aged 12 to Less Than 16 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      To evaluate the safety, tolerability and pharmacokinetics (PK) of MK0633 in adolescent
      mild-to-moderate asthma patients to permit further clinical investigation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of MK0633 in adolescent asthma patients.</measure>
    <time_frame>Blood and urine samples will be collected at specified intervals for 72 hours after study drug administration.</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK0633</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: MK0633</intervention_name>
    <description>patients will receive single 50mg oral dose with follow-up observation for 5 weeks.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is judged to be in good health, other than having mild to moderate asthma,
             based on medical history, physical examination, vital signs, and laboratory safety
             tests

          -  Patient has no clinically significant abnormality on electrocardiogram (ECG) performed
             at the prestudy (screening) visit and/or prior to administration of the initial dose
             of study drug

          -  Patient has at least 1 year of mild-to-moderate asthma

          -  Patient has been a nonsmoker for at least 6 months

          -  Patients of childbearing potential must agree to use a medically acceptable method of
             contraception during the study and for 90 days after the last dose of study drug

          -  Patients must be able to swallow tablets

        Exclusion Criteria:

          -  Patient has a history of clinically significant endocrine, gastrointestinal,
             cardiovascular, hematological, hepatic, immunological, renal, respiratory, other than
             asthma, or genitourinary abnormalities or diseases

          -  Patient has required a visit to a hospital or emergency room due to an asthma
             exacerbation within 3 months of the prestudy visit

          -  Patient has unresolved signs and symptoms of an upper respiratory tract infection
             (URI) or has had had an upper respiratory tract infection within 3 weeks prior to the
             prestudy visit

          -  Patient has a history of stroke, chronic seizures, or major neurological disorder

          -  Patient has a history of neoplastic disease

          -  Use of theophylline, Singulair (montelukast), Xolair (omalizumab), Zyflo amd Zyflo CR
             (zileuton), oral corticosteroids and oral beta agonists are excluded approximately 2
             weeks prior to administration of study drug and throughout the study

          -  Patient consumes alcoholic beverages
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2008</study_first_submitted>
  <study_first_submitted_qc>March 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2008</study_first_posted>
  <last_update_submitted>May 29, 2015</last_update_submitted>
  <last_update_submitted_qc>May 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

